The agreement covers the distribution of its DenerveX sSystem throughout Israel.
Dennis Moon, Medovex Executive Vice President, stated, "M.Fast Technologies LTD serves as a perfect call point fit for our mission to provide a successful distribution, sales and marketing foundation for our entry of the DenerveX System in the Middle East."
"With M.Fast Technologies LTD as a specialized distributor offering complex and innovative spine products throughout Israel, we are closing a gap while showing a professional presence in a major market," added Manfred Sablowski, Senior Vice President Sales & Marketing.
"Today's news importantly enables Medovex to expand the use of the DenerveX System into the Middle East, where M.Fast Technologies is a well established successful distributor. We expect the agreement will help in our efforts to increase worldwide adoption of the DenerveX System."
Sablowski continued, "Our goal remains to continuously improve our international market presence by expanding our network of strong distributors with knowledgeable sales and support personnel, and in close proximity to our customers."
Medovex already has distribution agreements for the DenerveX System in Germany, Spain, UK, Denmark, Norway, Sweden, Finland in Europe and Asia Pacific, as well as in select other countries around the world.
The Company's patented DenerveX System, currently in final development and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint.
Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.
The DenerveX System consists of the DenerveX device kit containing a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX System is designed to provide a minimally invasive treatment option which combines two actions into one device.
DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.
